227 related articles for article (PubMed ID: 16406476)
1. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity.
Höschele D
Toxicol In Vitro; 2006 Aug; 20(5):535-46. PubMed ID: 16406476
[TBL] [Abstract][Full Text] [Related]
2. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
3. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production.
Nerurkar PV; Pearson L; Frank JE; Yanagihara R; Nerurkar VR
Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1205-11. PubMed ID: 14983988
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.
Kakuda TN
Clin Ther; 2000 Jun; 22(6):685-708. PubMed ID: 10929917
[TBL] [Abstract][Full Text] [Related]
5. A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
Kohler JJ; Lewis W
Environ Mol Mutagen; 2007; 48(3-4):166-72. PubMed ID: 16758472
[TBL] [Abstract][Full Text] [Related]
6. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
Moyle G
Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
[TBL] [Abstract][Full Text] [Related]
7. HIV and mitochondrial toxicity in children.
Foster C; Lyall H
J Antimicrob Chemother; 2008 Jan; 61(1):8-12. PubMed ID: 17999978
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients.
Ciccosanti F; Corazzari M; Soldani F; Matarrese P; Pagliarini V; Iadevaia V; Tinari A; Zaccarelli M; Perfettini JL; Malorni W; Kroemer G; Antinori A; Fimia GM; Piacentini M
Antivir Ther; 2010; 15(3):377-90. PubMed ID: 20516557
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective.
Lewis W; Day BJ; Copeland WC
Nat Rev Drug Discov; 2003 Oct; 2(10):812-22. PubMed ID: 14526384
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
Lewis W
Antivir Ther; 2005; 10 Suppl 2():M13-27. PubMed ID: 16152703
[TBL] [Abstract][Full Text] [Related]
11. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
12. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
Dieterich DT
AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
[TBL] [Abstract][Full Text] [Related]
13. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
Nolan D; John M; Mallal S
Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings.
Miró O; López S; Cardellach F; Casademont J
Antivir Ther; 2005; 10 Suppl 2():M73-81. PubMed ID: 16152708
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial toxicity: myths and facts.
Moyle G
J HIV Ther; 2004 May; 9(2):45-7. PubMed ID: 15238876
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.
Maagaard A; Holberg-Petersen M; Kollberg G; Oldfors A; Sandvik L; Bruun JN
Antivir Ther; 2006; 11(5):601-8. PubMed ID: 16964828
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy.
Gingelmaier A; Grubert TA; Kost BP; Setzer B; Lebrecht D; Mylonas I; Mueller-Hoecker J; Jeschke U; Hiedl S; Friese K; Walker UA
Antivir Ther; 2009; 14(3):331-8. PubMed ID: 19474467
[TBL] [Abstract][Full Text] [Related]
18. [Impact of reverse transcriptase inhibitors on sperm mitochondrial and genomic DNA in assisted reproduction techniques].
Sergerie M; Martinet S; Kiffer N; Teulé R; Pasquier C; Bujan L
Gynecol Obstet Fertil; 2004 Oct; 32(10):841-9. PubMed ID: 15501159
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?
Maagaard A; Kvale D
J Antimicrob Chemother; 2009 Nov; 64(5):901-9. PubMed ID: 19740910
[TBL] [Abstract][Full Text] [Related]
20. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
